WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) posted a second-quarter net loss of $36.4 million or $0.32 per share, wider than $0.5 million or $0.01 per share in the prior year quarter.
On average, five analysts polled by Thomson Reuters expected the company to report a loss of $0.33 per share. Analysts' estimates typically excludes special items.
Revenue for the quarter decreased to $17.33 million from $42.56 million in the same quarter last year, while five Wall Street analysts expected revenues of $14.89 million.
This decrease in revenue year over year is primarily attributable to the completion as of December 31, 2010 of the amortization of the $125.0 million upfront payment received in 2009 from AstraZeneca for the NKTR-118 and NKTR-119 license agreement.
Copyright RTT News/dpa-AFX